ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025
Outcomes of localized corneal collagen crosslinking with a conventional device in progressive keratoconus.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the outcomes of localized crosslinking (L-CXL) for progressive keratoconus utilizing a standard CXL device.
designThis retrospective cohort study.
methodsincluded patients diagnosed with progressive keratoconus and treated with a localized cone-centered CXL (based on corneal topography) using the accelerated CXL protocol with a standard CXL device.
resultsWe Identified 24consecutive eyes. The average BDVA before CXL was 0.282 ± 0.35 LogMar, remained overall stable at 12-month post-surgery at 0.204 ± 0.173 LogMar (P = 0.395). Ten eyes (of eight patients) (42%) demonstrated an improvement in BDVA at 12 months of 1-4 lines and none of the other eyes lost BDVA. These eyes had significantly lower pre-operative BDVA than the stable eyes (P = 0.034). Ten eyes (of eight patients) (42%) demonstrated an improvement in K-max at 12 months post-operatively, of at least 1D; six of these eyes had improvement in both BDVA and Kmax. None of the eyes developed an increase in Kmax throughout the follow-up.
conclusionIn this series, cone-centered L-CXL, using a conventional CXL device resulted in significant stabilization and even improvements in BDVA and Kmax in almost half of the eyes, without significant adverse events. Addressing the CXL application onto the affected area results in beneficial results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.